Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab-Reference-Cited by-同舟云学术

Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab

Published:2018-07 Issue:4 Volume:12 Page:958-965
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Ridker Paul M,Rose Lynda M.,Kastelein John J.P.,Santos Raul D.,Wei Caimiao,Revkin James,Yunis Carla,Tardif Jean-Claude,Shear Charles L.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference25 articles.

1. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association;Gidding;Circulation,2015

2. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society;Nordestgaard;Eur Heart J,2013

3. LDL cholesterol: controversies and future therapeutic directions;Ridker;Lancet,2014

4. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES);de Ferranti;Circulation,2016

5. Cholesterol evaluation in young adults: absence of clinical trial evidence is not a reason to delay screening;Ridker;Ann Intern Med,2017

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treating Hypercholesterolemia in Older Adults for Primary Prevention of Cardiovascular Events;Drugs & Aging;2024-08-10

2. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better;American Journal of Preventive Cardiology;2024-06

3. Advances in familial hypercholesterolemia;Advances in Clinical Chemistry;2024

4. New Biological Therapies for Low-Density Lipoprotein Cholesterol;Canadian Journal of Cardiology;2023-12

5. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22